Protagonist Therapeutics, Inc. (PTGX)

26,09 +0,55 (+2,15%) Alla chiusura: 04:00PM EDT

Protagonist Therapeutics, Inc.

7707 Gateway Boulevard
Suite 140
Newark, CA 94560-1160
United States
510 474 0170
https://www.protagonist-inc.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 112

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Dinesh V. Patel Ph.D.	CEO, President, Secretary & Director	1,03M	N/D	1957
Mr. Asif Ali	Executive VP & Chief Financial Officer	631,04k	N/D	1974
Dr. Suneel K. Gupta Ph.D.	Chief Development Officer	719,21k	N/D	1959
Dr. Mark Smythe Ph.D.	Founder & VP Technology	N/D	N/D	1965
Mr. Mohammad Masjedizadeh Ph.D.	Executive VP & Chief Technical Officer	N/D	N/D	N/D
Mr. Matthew M. Gosling	Executive VP & General Counsel	N/D	N/D	1971
Ms. Carena Spivey	Head of HR & Senior VP of Human Resources	N/D	N/D	N/D
Dr. Ashok Bhandari Ph.D.	Executive VP & Chief Drug Discovery and Preclinical Development Officer	N/D	N/D	1964
Mr. Carter J. King	Executive Vice President of Business Development	N/D	N/D	1971
Ms. Abha Bommireddi	Executive Vice President of Portfolio & Program Management	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Governance aziendale

L'ISS Governance QualityScore di Protagonist Therapeutics, Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 7; diritti degli azionisti: 7; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.